Publication



Publications
Poster Presentation
NAV-003, Bispecific Targeting Mesothelin With Improved Cytotoxicity Against Humoral Immunosuppressed Tumors
Poster Presentation
The ADC NAV-001 targets mesothelin, deploys a novel payload, and is refractory to CA125 inhibition
Publication
NAV-006, next-gen rituximab with enhanced effector function by counteracting CA125 immunosuppression
Poster Presentation
HIO-3, a tumor-produced protein that binds the human IgG1 Fc CH3 domain and suppresses ADCC and CDC
Publication
CA125 suppresses ADCC via direct antibody binding and suppressed Fc-γ receptor engagement
Poster Presentation
BRITE Technology to enhance rituximab effector function by counteracting CA125-mediated immunosuppression
Publication
Tumor-shed antigen CA125 blocks complement-mediated killing via suppression of C1q-antibody binding
Poster Presentation